( NASDAQ-SMALL:BLRX,TelAviv:BLRX )

News from biolinerx A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

May 16, 2016, 07:00 ET BioLineRx and MaRS Innovation Sign Framework Collaboration Agreement

BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising...


May 10, 2016, 08:00 ET BioLineRx to Report First Quarter 2016 Results on May 17, 2016

BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising...


Apr 04, 2016, 07:00 ET BioLineRx's Novel Treatment for Non-Surgical Removal of Skin Lesions Receives CE Mark Approval

BioLineRx Ltd. (NASDAQ/TASE: BLRX) announced today that its partner, Omega Pharma, now part of Perrigo, has received CE Mark approval for BL-5010...


Mar 29, 2016, 07:00 ET BioLineRx Reports Successful Top-Line Results in Phase 2 Trial for AML

BioLineRx (NASDAQ/TASE: BLRX) announced today positive top-line results from BL-8040's Phase 2 clinical trial in relapsed or refractory acute...


Mar 10, 2016, 06:00 ET BioLineRx to Present at 2016 Annual Roth Conference in Southern California on March 14

BioLineRx (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising...


Mar 03, 2014, 16:35 ET BioLineRx Announces Underwritten Public Offering of its American Depositary Shares

 BioLineRx (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing...


Feb 24, 2014, 07:00 ET BioLineRx Appoints Dr. Sandra Panem to Board of Directors

 BioLineRx (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing...


Feb 12, 2014, 07:00 ET BioLineRx Announces Positive Preclinical Results for Novel Treatment for Chronic Myeloid Leukemia

BioLineRx (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising...


Jan 23, 2014, 07:00 ET BioLineRx Receives Orphan Drug Designation for Novel Stem Cell Mobilization Treatment

 BioLineRx (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing...


Jan 21, 2014, 07:00 ET BioLineRx Receives Approval to Commence Pivotal Trial for Novel Skin Lesion Treatment

 BioLineRx (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing...


Jan 13, 2014, 07:00 ET BioLineRx Announces Regulatory Submission for Novel Stem Cell Mobilization Treatment

 BioLineRx (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing...


Jan 08, 2014, 07:00 ET BioLineRx and JHL Biotech to Collaborate on Type 1 Diabetes Antibody Treatment

 BioLineRx (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing...


Jan 07, 2014, 08:00 ET BioLineRx to Present at Biotech Showcase Conference in San Francisco

 BioLineRx (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing...


Dec 18, 2013, 07:00 ET BioLineRx Enters Clinic with Novel Treatment for Celiac Disease

 BioLineRx (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing...


Dec 16, 2013, 07:00 ET BioLineRx Announces Promising Initial Phase 2 Results of Acute Myeloid Leukemia Treatment

 BioLineRx (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing...


Dec 10, 2013, 07:00 ET BioLineRx Presents Positive Preclinical Results of Acute Myeloid Leukemia Treatment at ASH Conference

BioLineRx (NASDAQ: BLRX; TASE: BLRX), a biopharmaceutical development company, announced today that positive preclinical results of BL-8040...


Dec 09, 2013, 12:34 ET Edison grows its international biopharmaceutical presence with initiation of coverage of BioLineRx

Edison Investment Research, a leading international investment research firm, announces the initiation of coverage of BioLineRx a dual...